

Bioequivalence Study of Two Oral Doxycycline Formulations (Doxysol[®] and Doxymed[®]) in Healthy Broiler Chickens

Ahmed M. Soliman^{1*}, Mohamed Aboubakr², Mohamed El-Hewaity³

¹Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt

²Department of Pharmacology, Faculty of Veterinary Medicine, Benha University, Qaliobiya, Egypt

³Department of Pharmacology, Faculty of Veterinary Medicine, University of Sadat City, Minoufiya, Egypt

Email: *galalpharma@hotmail.com, *galalpharma@cu.edu.eg

Received 4 December 2014; accepted 20 December 2014; published 13 January 2015

Copyright © 2015 by authors and Scientific Research Publishing Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY).

<http://creativecommons.org/licenses/by/4.0/>



Open Access

Abstract

Aims: The present study was designed to assess the comparative bio-equivalence of Doxysol[®] and Doxymed[®] in healthy broiler chickens after oral administration of both products in a dose of 20 mg doxycycline/kg.b.wt. **Materials and Methods:** Twenty broiler chickens were divided into two groups. The first group was designed to study the pharmacokinetics of Doxysol, while the 2nd group was designed to study the pharmacokinetics of Doxymed. Each broiler chickens in both groups were injected intravenously with 20 mg doxycycline/kg.b.wt. Blood samples were obtained from the wing vein and collected immediately before and at 5, 15, 30 minute, 1, 2, 4, 6, 8, 12 and 24 hours after a single intravenous or oral administration. **Results:** Doxycycline in both products obeyed a two compartments open model following I.V. injection in a dose of 20 mg/kg.b.wt. The disposition kinetics of Doxysol[®] and Doxymed[®] following oral administration of 20 mg doxycycline base/kg.b.wt. revealed that the maximum blood concentration [C_{max}] were 4.70 and 4.65 $\mu\text{g/ml}$ and attained at [t_{max}] of 1.30 and 1.40 hours, respectively. Doxycycline in Doxysol[®] and Doxymed[®] was eliminated with half-lives [$t_{0.5(\beta)}$] equal to 1.98 and 2.31 hours, respectively. The mean systemic bioavailability of doxycycline in Doxysol[®] and Doxymed[®] after oral administration in healthy chickens was 92.57 and 88.21%, respectively. **Conclusion:** Doxymed[®] is bioequivalent to Doxysol[®] since $C_{max\text{ test}}/C_{max\text{ reference}}$ and $AUC_{\text{test}}/AUC_{\text{reference}}$ ratios were 99% and 90%, respectively.

Keywords

Bioequivalence, Doxycycline, Broiler Chickens, Pharmacokinetics

*Corresponding author.

1. Introduction

Doxycycline is a semi-synthetic bacteriostatic tetracycline and a broad-spectrum antibiotic against Gram-negative and Gram-positive aerobic and anaerobic bacteria, Rickettsiae, Chlamydiae, Mycoplasmas and some protozoa [1] [2]. Pharmacokinetics properties of doxycycline are superior than older tetracycline, in terms of higher lipid solubility, complete *absorption*, better tissue distribution, longer elimination half-life and lower affinity for calcium [3] [4]. The *in vitro* antimicrobial activity of doxycycline is more effective than other tetracycline for the treatment of respiratory, urinary and gastrointestinal tract diseases [5] [6].

The bioavailability and bioequivalence studies play an important role in determining therapeutic efficacy to register the generic drug products according to the Food and Drug Administration (FDA) regulations [7]. Bioavailability is defined as the rate and extent to which an active drug ingredient is absorbed and becomes available at the site of drug action. In case of bioequivalence it is defined as statistically equivalent bioavailability between two products at the same molar dose of the therapeutic moiety under similar experimental conditions [7] [8]. The drug products are said to be bioequivalent if they are pharmaceutical equivalents or pharmaceutical alternatives and if their rate and extent of absorption do not show a significant differences statistically according to the FDA regulations [7].

The aim of this study is to evaluate bioequivalence of two oral doxycycline powder (Doxysol[®] and Doxymed[®]) after oral administration of a single dose in broiler chickens.

2. Materials and Methods

2.1. Drugs

Doxysol[®]: is manufactured by Ascor Chimici, Italy. It is dispensed as oral powder. Each 100 g contains 20 g doxycycline hydrochloride.

Doxymed[®]: is manufactured by Medmac Co., Amman, Jordan, as oral powder. Each 100 g contains 20 g doxycycline hydrochloride.

2.2. Broiler Chickens and Experimental Design

Twenty healthy broiler chickens (40 - 45 days old and weighing 2 - 2.30 kg) were chosen from Tanta Poultry Farm, Egypt. They were kept individually in cages, within a ventilated, heated room (20°C), and 14 hours of day light. They received a standard commercial ration free from any antibiotics for 30 days before starting the experiment to insure complete clearance of any anti-bacterial substances from their bodies. Water was offered *ad-libitum*.

2.3. Bioequivalence Study of Doxysol[®] and Doxymed[®]

Twenty broiler chickens were used to study the bio-equivalence of Doxysol[®] and Doxymed[®] after oral administration. Broiler chickens were divided into two groups. The first group comprises ten broiler chickens to study the pharmacokinetics of Doxysol[®]. The 2nd group (10 broiler chickens) was used to study the pharmacokinetics of Doxymed[®]. Each broiler chickens in both groups were injected intravenously with 20 mg doxycycline standard activity/kg.b.wt. Broiler chickens were left for 15 days to ensure complete excretion of doxycycline from their bodies. Broiler chickens in the 1st group were administered orally (intra-crop) with Doxysol[®] in a dose of 20 mg doxycycline/kg.b.wt (1 gram of product/1 liter drinking water), while broiler chickens in the 2nd group were administered orally with Doxymed[®] in a dose of 20 mg doxycycline/kg.b.wt (1 gram of product/1 liter drinking water)/kg.b.wt.

2.4. Blood Samples

Blood samples were obtained from the wing vein (1 ml) and collected in test tubes immediately before and at 5, 15, 30 minute, 1, 2, 4, 6, 8, 12 and 24 hours after a single intravenous or oral administration (groups 1 and 2). Samples were centrifuged at 3000 rpm for 10 minutes and the obtained sera were used for the estimation of doxycycline concentration. The serum samples were stored at -20°C until analysis, and the assay was performed within a week of obtainment.

2.5. Analytical Procedure

Arret *et al.* [9] described a rapid agar-diffusion assay for the quantitative determination of doxycycline in small

volumes of blood by using *Bacillus subtilis* (ATCC 6633). The used test organism for the microbiological assay was obtained from Microbiology Department, Faculty of Veterinary Medicine, Cairo University, Egypt.

2.6. Pharmacokinetic Analysis

The pharmacokinetic parameters were determined for each individual sample according to Baggot [10]. Serum concentrations of the two formulations of doxycycline after a single oral administration were subjected to a non-compartmental pharmacokinetic analysis using computerized program, WinNonline 4.1 (Pharsight, USA). Values calculated were: AUC, area under the blood concentration (C_{pt}) time (t) curve to infinity, elimination rate constant (k_{el} , calculated as the slope of the terminal phase of the serum concentration curve), terminal half-life ($t_{0.5}$, where $t_{0.5} = 0.693/k_{el}$), volume of distribution at steady state ($Vd_{(ss)}$), body clearance ($Cl_{(B)}$), the peak serum concentration (C_{max}) and the time to peak concentration (t_{max}). The rate of absorption after oral administration was determined by comparing the area under the serum concentration curve (AUC_{oral}) with that obtained following intravenous injection ($AUC_{i.v.}$) in the same chicken.

$$\text{Bioavailability} = \frac{(AUC)_{oral} \times D_{i.v.}}{(AUC)_{i.v.} \times D_{oral}} \times 100$$

where: D_{iv} = Dose of i.v. administration .

D_{oral} = Dose of oral administration.

The following equation according to FDA regulation [7] was performed to prove that the tested product is bioequivalent to the reference product in the study.

$$\frac{AUC_{(test)}}{AUC_{(reference)}} \text{ or } \frac{C_{max(test)}}{C_{max(reference)}}$$

2.7. Statistical Analysis

Obtained data was analyzed by analysis of variance (ANOVA). The differences were considered significant when $p < 0.05$. All the data are expressed as mean \pm SE.

3. Results

The mean serum concentration of doxycycline in broiler chickens were determined up to 24 h and were not detected in all chickens 48 h post single oral and intravenous administration. The mean blood concentrations-time profile ($\mu\text{g/ml}$) of doxycycline in Doxysol[®] and Doxymed[®] after intravenous administration of 20 mg doxycycline/kg.b.wt. in broiler chickens are shown in (Table 1 and Figure 1).

The mean pharmacokinetic parameters of doxycycline (Doxysol[®] and Doxymed[®]) after intravenous administration of 20 mg doxycycline/kg.b.wt. in broiler chickens are shown in Table 2. The systemic bioavailability (F%) was 92.57 and 88.21% for Doxysol[®] and Doxymed[®], respectively.

Doxycycline in both formulations after intravenous administration could be described in a two compartments-open model. Doxycycline intravenous administration in a dose of 20 mg/kg.b.wt. revealed a high volume of distribution (exceeded than one L/kg) calculated by extrapolation [V_{dB}] and steady state [V_{dss}] method, which are factors made doxycycline is highly distributed in all body tissues. A factor revealed that doxycycline is the drug of choice for attacking the systemic infections caused by sensitive organisms.

The mean serum concentrations of doxycycline in Doxysol[®] and Doxymed[®] following oral administration of 20 mg doxycycline/kg.b.wt. in broiler chickens are shown in (Table 3 and Figure 2).

The mean pharmacokinetic parameters of doxycycline in Doxysol[®] and Doxymed[®] after oral administration of 20 mg doxycycline/kg.b.wt. in broiler chickens are shown in (Table 4).

The disposition kinetics of doxycycline in Doxysol[®] and Doxymed[®] following oral administration of 20 mg doxycycline base/kg.b.wt. revealed that the maximum blood concentration [C_{max}] were 4.70 and 4.65 $\mu\text{g/ml}$ and attained at [T_{max}] of 1.30 and 1.40 hours, respectively.

The 90% confidence intervals for the mean ratio of C_{max} and AUC of the reference and tested formulations were within bioequivalence range and summarized in Table 5.




Figure 1. Semilogarithmic plot showing the serum concentrations-time profile of doxycycline in Doxysol® and Doxymed® following intravenous administration at a dose of 20 mg doxycycline/kg.b.wt. in broiler chickens (n = 10).




Figure 2. Semilogarithmic plot showing the serum concentrations-time profile of doxycycline in Doxysol® and Doxymed® following oral administration at a dose of 20 mg doxycycline/kg.b.wt. in broiler chickens (n = 10).

4. Discussion

Antibiotics are widely used as veterinary drugs or as feed additives to promote growth [11]-[16]. The pharmacokinetics of doxycycline was reported in chickens following different routes of administrations [17]-[21]. However, the current study was designed to investigate pharmacokinetics and bioequivalence of doxycycline of two powder formulations (Doxysol® and Doxymed®) after oral administration in broiler chickens.

Doxycycline in both formulations after i.v. administration could be described in a two compartments-open model. This indicated that, doxycycline distributed in the body of broiler chickens in two compartments; a central one which represent blood and highly perfused organs (kidney-liver-spleen-heart) and a 2nd peripheral compartment which represented by skin and connective tissues [6]. Doxycycline peak plasma concentration for both formulations was higher than the minimum inhibitory concentrations (MICs) for *Mycoplasma gallisepticum* (0.2

Table 1. Mean ($X \pm S.E$) serum concentrations ($\mu\text{g/ml}$) of doxycycline in Doxysol[®] and Doxymed[®] following intravenous administration of 20 mg doxycycline/kg.b.wt. in broiler chickens ($n = 10$).

Time after administration (h)	Doxysol [®]	Doxymed [®]
5 min.	9.15 \pm 0.60	8.70 \pm 0.63
0.25	7.90 \pm 0.45	7.90 \pm 0.28
0.50	6.40 \pm 0.70	6.35 \pm 0.63
1	5.20 \pm 0.55	5.00 \pm 0.90
2	4.10 \pm 0.35	4.15 \pm 0.35
4	2.60 \pm 0.27	2.45 \pm 0.60
6	1.60 \pm 0.50	1.70 \pm 0.35
8	1.05 \pm 0.06	1.10 \pm 0.08
12	0.70 \pm 0.08	0.65 \pm 0.07
24	0.35 \pm 0.06	0.25 \pm 0.04

Table 2. Mean ($X \pm S.E$) pharmacokinetic parameters of doxycycline in Doxysol[®] and Doxymed[®] following intravenous administration of 20 mg doxycycline/kg.b.wt. in broiler chickens ($n = 10$).

Parameter	Unit	Doxysol [®]	Doxymed [®]
$^{\circ}\text{C}$	$\mu\text{g/ml}$	8.95 \pm 0.75	8.15 \pm 0.50
A	$\mu\text{g/ml}$	5.35 \pm 0.65	4.70 \pm 0.29
α	h^{-1}	3.75 \pm 0.45	4.10 \pm 0.30
$T_{0.5(\alpha)}$	h	0.18 \pm 0.09	0.17 \pm 0.08
V_c	L/kg	3.40 \pm 0.08	3.10 \pm 0.06
$V_{d(B)}$	L/kg	4.80 \pm 0.07	3.95 \pm 0.15
$V_{d(\text{area})}$	L/kg	5.75 \pm 0.15	5.15 \pm 0.60
V_{dss}	L/kg	5.05 \pm 0.13	4.70 \pm 0.25
k_{12}	h^{-1}	0.85 \pm 0.22	0.90 \pm 0.08
k_{21}	h^{-1}	1.25 \pm 0.05	1.15 \pm 0.07
B	$\mu\text{g/ml}$	3.60 \pm 0.24	3.45 \pm 0.23
β	h^{-1}	0.075 \pm 0.030	0.065 \pm 0.004
$T_{0.5(\beta)}$	h	9.24 \pm 0.60	10.66 \pm 0.85
k_{13}	h^{-1}	0.37 \pm 0.05	0.35 \pm 0.05
Cl_B	L/kg/h	0.015 \pm 0.002	0.017 \pm 0.003
AUC	Mg·h/ml	26.25 \pm 1.60	24.60 \pm 2.40

Table 3. Mean ($X \pm S.E$) serum concentrations ($\mu\text{g/ml}$) of doxycycline in Doxysol[®] and Doxymed[®] following oral administration of 20 mg doxycycline/kg.b.wt. in broiler chickens ($n = 10$).

Time after administration (h)	Doxysol [®]	Doxymed [®]
5 min.	1.05 \pm 0.30	0.95 \pm 0.44
0.25	2.10 \pm 0.26	1.90 \pm 0.60
0.50	2.60 \pm 0.70	2.55 \pm 0.30
1	3.30 \pm 0.39	3.25 \pm 0.50
2	4.60 \pm 0.80	4.50 \pm 0.45
4	4.00 \pm 0.45	3.90 \pm 0.33
6	3.20 \pm 0.50	3.10 \pm 0.80
8	2.30 \pm 0.60	2.35 \pm 0.60
12	1.75 \pm 0.85	1.80 \pm 0.35
24	0.90 \pm 0.06	1.05 \pm 0.07

Table 4. Mean ($X \pm S.E$) pharmacokinetic parameters of doxycycline in Doxysol[®] and Doxymed[®] following oral administration of 20 mg doxycycline/kg.b.wt. in broiler chickens (n = 10).

Parameter	Unit	Doxysol [®]	Doxymed [®]
A	µg/ml	3.75 ± 0.38	3.66 ± 0.40
k_{ab}	h ⁻¹	2.65 ± 0.26	2.28 ± 0.30
$T_{0.5(ab)}$	h	0.26 ± 0.07	0.27 ± 0.06
B	µg/ml	3.00 ± 0.36	2.92 ± 0.25
β	h ⁻¹	0.04 ± 0.003	0.05 ± 0.002
$T_{0.5(\beta)}$	h	17.32 ± 0.25	13.86 ± 0.35
T_{max}	h	1.30 ± 0.14	1.40 ± 0.18
C_{max}	µg/ml	4.70 ± 0.60	4.65 ± 0.50
AUC	µg-h/ml	24.30 ± 1.60	21.70 ± 1.48
Bioavailability	%	92.57 ± 3.00	88.21 ± 2.62

Table 5. Bioequivalence between Doxysol[®] (reference) and Doxymed[®] (test) formulations.

Parameters	Reference	Test	90% CI lower/upper	T/R (%)	Acceptable range (%)	Conclusion
C_{max} (µg/ml)	4.7 ± 0.60	4.65 ± 0.50	88.68 - 112.19	98.93	75 - 133	BE
AUC (µg-h/ml)	24.30 ± 1.60	21.70 ± 1.48	88.98 - 89.57	89.30	80 - 125	BE

BE: Bioequivalence.

Doxycycline in both formulations after i.v. administration could be described in a two compartments-open model. This indicated that, doxycycline distributed in the body of broiler chickens in two compartments; a central one which represent blood and highly perfused organs (kidney-liver-spleen-heart) and a 2nd peripheral compartment which represented by skin and connective tissues [6]. Doxycycline peak plasma concentration for both formulations was higher than the minimum inhibitory concentrations (MICs) for Mycoplasma gallisepticum (0.2 µg/ml) [22], Mycoplasma pneumoniae (<0.5 µg/ml), Staphylococcus aureus (0.25 µg/ml) [23], Streptococcus pneumoniae (<0.4 µg/ml) [24] and E. coli (1 - 4 µg/ml) [25]. However, doxycycline peak plasma concentration for both formulations was lower than the MICs for Pseudomonas aeruginosa (>64 µg/ml) [8] and Enterococcus faecalis (8 to 32 µg/ml) [26]. This emerge the therapeutic usefulness of doxycycline in control many susceptible bacteria. Doxycycline in Doxysol[®] and Doxymed[®] was eliminated with half-lives [$t_{0.5(\beta)}$] equal to 17.32 and 13.86 hours, respectively. The long $t_{0.5}$ is a clear characteristic of doxycycline in different species, which range from 4.2 to 16.6 h [1] [17] [18] [27] [28].

The oral bioavailability of Doxysol[®] and Doxymed[®] indicated a good absorption from GIT. This is indicated that both products are advised to be given orally in case of acute bacterial attacks in blood and other organs [17] [18]. No significant differences were observed between the pharmacokinetics parameters of the two formulations; these results were showing the bioequivalence of the two formulations were according to the criteria established by FDA [7].

Bioequivalence study is a test to assure the clinical efficacy of a generic versus brand drugs [7]. Bioequivalence refers to a comparison between generic formulations of a drug, or a product in which a change has been made in one or more of the ingredients or in the manufacturing process, and a reference dosage form of the same drug [29].

The 90% confidence intervals for the mean ratio of C_{max} and AUC of the reference and tested formulations were 98.93% and 89.30%, respectively. These values falls within the EMEA bioequivalence acceptance range of 85% - 125% for both T_{max} and AUC and between 75% - 133% for C_{max} [30].

5. Conclusion

Based on the above pharmacokinetic and statistical results that calculated in the current study, we concluded that Doxymed[®] manufactured by Medmac-Jordan is bioequivalent to Doxysol[®] manufactured by Ascor Chimici-Italy and both products can be used as interchangeable drug in veterinary medicine practice especially in poultry

industrial sector.

References

- [1] Jha, V.K., Jayachandran, C., Singh, M.K. and Singh, S.D. (1989) Pharmacokinetic Data on Doxycycline and Its Distribution in Different Biological Fluids in Female Goats. *Veterinary Research Communications*, **13**, 11-16. <http://dx.doi.org/10.1007/BF00366847>
- [2] Prats, G., Elkorchi, G., Giralt, M., *et al.* (2005) PK and PK/PD of Doxycycline in Drinking Water after Therapeutic Use in Pigs. *Journal of Veterinary Pharmacology and Therapeutics*, **28**, 525-530. <http://dx.doi.org/10.1111/j.1365-2885.2005.00700.x>
- [3] Riond, J.L. and Riviere, J.E. (1990) Pharmacokinetics and Metabolic Inertness of Doxycycline in Young Pigs. *American Journal of Veterinary Research*, **51**, 1271-1275.
- [4] Goren, E., De-Jong, W., Doornenbal, P., *et al.* (1988) Therapeutic Efficacy of Doxycycline Hyclate in Experimental *Escherichia coli* Infection in Broilers. *Vet Q*, **10**, 48-52. <http://dx.doi.org/10.1080/01652176.1988.9694145>
- [5] Croubels, S., Baert, K., De Busser, J. and De Backer, P. (1998) Residue Study of Doxycycline and 4-Epidoxycycline in Pigs Medicated via Drinking Water. *Analyst*, **123**, 2733-2736. <http://dx.doi.org/10.1039/a804936j>
- [6] Abd El-Aty, A.M., Goudah, A. and Zhou, H.H. (2004) Pharmacokinetics of Doxycycline after Administration as a Single Intravenous Bolus and Intramuscular Doses to Non-Lactating Egyptian Goats. *Pharmacological Research*, **49**, 487-491.
- [7] Chen, M.L., Shah, V., Patnaik, R., *et al.* (2001) Bioavailability and Bioequivalence: An FDA Regulatory Overview. *Pharmaceutical Research*, **18**, 1645-1650. <http://dx.doi.org/10.1023/A:1013319408893>
- [8] Toutain, P.L. and Bousquet-Melou, A. (2004) Bioavailability and Its Assessment. *Journal of Veterinary Pharmacology and Therapeutics*, **27**, 455-466. <http://dx.doi.org/10.1111/j.1365-2885.2004.00604.x>
- [9] Arret, B., Johnson, D. and Kirshbaum, A. (1971) Outline of Details for Microbiological Assay of Antibiotics. *Journal of Pharmaceutical Sciences*, **60**, 1689-1694. <http://dx.doi.org/10.1002/jps.2600601122>
- [10] Baggot, J. (1978) Some Aspects of Clinical Pharmacokinetics in Veterinary Medicine. *Journal of Veterinary Pharmacology and Therapeutics*, **1**, 5-18. <http://dx.doi.org/10.1111/j.1365-2885.1978.tb00300.x>
- [11] Yoshida, M., Kubota, D., Yonezawa, S., Nakamura, H., Azechi, H. and Terakado, N. (1971) Transfer of Dietary Spiramycin into the Eggs and Its Residue in the Liver of Laying Hen. *Japanese Journal of Antibiotics*, **8**, 103-110.
- [12] Yoshida, M., Kubota, D., Yonezawa, S., Nakamura, H., Azechi, H. and Terakado, N. (1973) Transfer of Dietary Doxycycline into the Eggs and Its Residue in the Liver of Laying Hen. *Japanese Journal of Antibiotics*, **10**, 29-36.
- [13] Roadaut, B., Moretain, J.P. and Boisseau, J. (1987) Excretion of Oxytetracycline in Eggs after Medication of Laying Hens. *Food Additives and Contaminants*, **4**, 297-307. <http://dx.doi.org/10.1080/02652038709373639>
- [14] Roadaut, B. and Moretain, J.P. (1990) Residues of Macrolide Antibiotics in Eggs Following Medication of Laying Hens. *British Poultry Science*, **31**, 661-675. <http://dx.doi.org/10.1080/00071669008417297>
- [15] Yoshimura, H., Osawa, N., Rasa, F.S.C., Hermawati, D., Werdiningsih, S., Isriyanthi, N.M.R. and Sugimori, T. (1991) Residues of Doxycycline and Oxytetracycline in Eggs after Medication via Drinking Water to Laying Hens. *Food Additives and Contaminants*, **8**, 65-69. <http://dx.doi.org/10.1080/02652039109373956>
- [16] Omija, B., Mitema, E.S. and Maitho, T.E. (1994) Oxytetracycline Residue Levels in Chicken Eggs after Oral Administration of Medicated Drinking Water to Laying Chickens. *Food Additives and Contaminants*, **11**, 641-647. <http://dx.doi.org/10.1080/02652039409374265>
- [17] Anadon, A., Martinez-Larranaga, M.R., Diaz, M.J., Bringas, P., Fernandez, M.C., Fernandez-Cruz, M.L., *et al.* (1994) Pharmacokinetics of Doxycycline in Broiler Chickens. *Avian Pathology*, **23**, 79-90. <http://dx.doi.org/10.1080/03079459408418976>
- [18] Laczay, P., Semjen, G., Lehel, J. and Nagy, G. (2001) Pharmacokinetics and Bioavailability of Doxycycline in Fasted and Non-Fasted Broiler Chickens. *Acta Veterinaria Hungarica*, **49**, 31-37. <http://dx.doi.org/10.1556/AVet.49.2001.1.5>
- [19] Ismail, M.M. and El-Kattan, Y.A. (2004) Disposition Kinetics of Doxycycline in Chickens Naturally Infected with *Mycoplasma gallisepticum*. *British Poultry Science*, **45**, 550-556. <http://dx.doi.org/10.1080/00071660400001058>
- [20] Hantash, T.M., Abu-Basha, E.A., Roussan, D.A. and Abudabos, A.M. (2008) Pharmacokinetics and Bioequivalence of Doxycycline (Providox[®] and Doxyveto 50 S[®]) Oral Powder Formulations in Chickens. *International Journal of Poultry Science*, **7**, 161-164. <http://dx.doi.org/10.3923/ijps.2008.161.164>
- [21] El-Gendy, A.Y., Atef, M., Amer, A.M. and Kamel, G.M. (2010) Pharmacokinetics and Tissue Distribution of Doxycycline in Broiler Chickens Pretreated with Either: Diclazuril or Halofuginone. *Food and Chemical Toxicology*, **48**, 3209-3214. <http://dx.doi.org/10.1016/j.fct.2010.08.024>

- [22] Takahashi, I. and Yoshida, T. (1989) Antimycoplasmal Activities of Ofloxacin and Commonly Used Antimicrobial Agents on *Mycoplasma gallisepticum*. *Japanese Journal of Antibiotics*, **42**, 1166-1172.
- [23] Bryant, J.E., Brown, M.P., Gronwall, R.R. and Merritt, K.A. (2000) Study of Intra-Gastric Administration of Doxycycline: Pharmacokinetics Including Body Fluid, Endometrial and Minimum Inhibitory Concentrations. *Equine Veterinary Journal*, **32**, 233-238. <http://dx.doi.org/10.2746/042516400776563608>
- [24] Aronson, A.L. (1980) Pharmacotherapeutics of the Newer Tetracycline. *Journal of the American Veterinary Medical Association*, **176**, 1061-1068.
- [25] Moskowitz, S.M., Foster, J.M., Emerson, J. and Burns, J.L. (2004) Clinically Feasible Biofilm Susceptibility Assay for Isolates of *Pseudomonas aeruginosa* from Patients with Cystic Fibrosis. *Journal of Clinical Microbiology*, **42**, 1915-1922. <http://dx.doi.org/10.1128/JCM.42.5.1915-1922.2004>
- [26] Hoelscher, A.A., Bahcall, J.K. and Maki, J.S. (2006) *In Vitro* Evaluation of the Antimicrobial Effects of a Root Canal Sealer-Antibiotic Combination against *Enterococcus faecalis*. *Journal of Endodontics*, **32**, 145-147. <http://dx.doi.org/10.1016/j.joen.2005.10.031>
- [27] Santos, M.D., Vermeersch, H., Remon, J.P., Schelkens, M., De Backer, P., Bree, H.J.J., *et al.* (1996) Pharmacokinetics and Bioavailability of Doxycycline in Turkeys. *Journal of Veterinary Pharmacology and Therapeutics*, **19**, 274-280. <http://dx.doi.org/10.1111/j.1365-2885.1996.tb00049.x>
- [28] Baert, K., Croubels, S., Gasthuys, F., De Busser, J. and De Backer, P. (2000) Pharmacokinetics and Oral Bioavailability of Doxycycline Formulation (Doxycycline 75%) in Non-Fasted Young Pigs. *Journal of Veterinary Pharmacology and Therapeutics*, **23**, 45-48. <http://dx.doi.org/10.1046/j.1365-2885.2000.00235.x>
- [29] Alvinerie, M., Lacoste, E., Sutra, J.F. and Chartier C. (1999) Some Pharmacokinetic Parameters of Eprinomectin in Goats Following Pour-On Administration. *Veterinary Research Communications*, **23**, 449-455. <http://dx.doi.org/10.1023/A:1006373609314>
- [30] Ozdemir, N. and Yildirim, M. (2006) Bioequivalence Study of Two Long-Acting Oxytetracycline Formulations in Sheep. *Veterinary Research Communications*, **30**, 929-934. <http://dx.doi.org/10.1007/s11259-006-3235-2>

Scientific Research Publishing (SCIRP) is one of the largest Open Access journal publishers. It is currently publishing more than 200 open access, online, peer-reviewed journals covering a wide range of academic disciplines. SCIRP serves the worldwide academic communities and contributes to the progress and application of science with its publication.

Other selected journals from SCIRP are listed as below. Submit your manuscript to us via either submit@scirp.org or [Online Submission Portal](#).

